Development of high-grade non-Hodgkin's lymphoma is a possible complication of chronic lymphocytic leukaemia/ small lymphocytic lymphoma, known as Richter's syndrome (RS). Treatment for RS includes systemic chemotherapy and, recently, allogeneic stem cell transplantation (SCT). We describe a patient with B-chronic lymphocytic leukaemia who developed RS 4 months after allogeneic SCT from an HLA-identical sibling. The RS presented with systemic symptoms, lymphadenopathy, pancytopenia and serum lactate dehydrogenase elevation. The patient was treated with immunosuppressive drug withdrawal and a donor lymphocyte infusion (DLI) of 1 Â 10 7 CD3/kg, leading to the disappearance of all symptoms and the attainment of complete donor chimerism. After 18 months of the therapeutic DLI, the patient continues in complete remission.
kin's lymphoma; Richter's syndrome; donor lymphocyte infusion; graft-versus-leukaemia effect; graft-versus-lymphoma effect Large-cell non-Hodgkin's lymphoma (NHL) complicates the course of chronic lymphatic leukaemia/small cell lymphoma in about 3% of the cases. 1 It was first described by Richter in 1928 as a syndrome of weight loss, abdominal discomfort, diffuse lymphadenopathy, massive organomegaly and lymphocytosis. 2 The so-called Richter's syndrome (RS) presents mainly with systemic symptoms, progressive lymphadenopathy and increased levels of lactate dehydrogenase (LDH). Less commonly reported features include extranodal involvement and monoclonal gammopathy. Clinical deterioration is accompanied by a shortened survival. 3 Treatment modalities for RS include systemic chemotherapy with fludarabine-containing regimens, CHOPbased regimens, or other chemotherapy schedules used for high-grade lymphomas, such as MACOP-B and ASHAP, with or without adjuvant radiotherapy. Overall response rate in the patient group described by Robertson et al 3 was 42%, and the median survival was 5 months. With fludarabine-based regimens the median survival is 17 months. 1 Moreover, those patients who respond well to treatment may enjoy prolonged survival. 3 Recently, allogeneic stem cell transplantation (SCT) has become a new strategy for the treatment of patients with RS, and preliminary results suggest that this may improve the prognosis when compared with conventional chemotherapy. 4 We report a case of high-grade NHL that appeared 4 months after allogeneic SCT for chronic lymphatic leukaemia (CLL), jointly with the reappearance of the original low-grade malignancy. The patient was treated with immunosuppressive drug withdrawal and one donor lymphocyte infusion (DLI), leading to complete remission of both the high-grade lymphoma and the CLL. To the best of our knowledge, this is the first report of a patient who developed RS after allogeneic SCT and was successfully treated by the induction of a graft-versus-leukaemia/ lymphoma (GVL) effect using immunosuppressive drug withdrawal and DLI.
Case report
A now 50-year-old diabetic woman presented 5 years ago with multiple lymphadenopathies, mainly in the submandibular, supraclavicular and axillary areas, and a lymphocytosis of 4.9 Â 10 9 /l. The peripheral blood smear showed small lymphocytes and occasional smear cells (Figure 1 ).
Lymphocyte immunophenotyping on peripheral blood revealed a 5/6 CLL score. 5 A bone marrow biopsy showed nodular infiltration by small mature B-lymphocytes. B-cell small lymphocytic lymphoma/CLL was diagnosed based on examination of a lymph node biopsy. Therapy with chlorambucil and prednisone was administered over a 6-month period, and the patient achieved a partial response.
Owing to increasing lymphadenopathy, 2 years later, the patient received chlorambucil for a whole year and attained a second partial response. She refused more intensive treatment, but a few months later she accepted two courses of a second-line protocol of fludarabine, cyclophosphamide and mitoxantrone. Treatment had to be stopped because of pancytopenia with progressive lymphadenopathy. Fever, night sweats, anorexia and loss of more than 10% of body weight were also present. RS was ruled out on a new lymph node biopsy. However, approximately 75% of tumour cells showed the p53 mutation. Diffuse bone marrow infiltration by small lymphocytes was also evident.
An allogeneic peripheral blood SCT from an HLAidentical sibling was planned. The conditioning regimen included etoposide, 40 mg/kg intravenously (i.v.) in a single dose, cyclophosphamide, 120 mg/kg i.v. in two doses, and fractionated total body irradiation to a total dose of 13 Gy. CD34+ cells were selected from the donor apheresis product using the immunomagnetic cell separation method. The patient was infused with 6.86 Â 10 6 CD34+ cells/kg. Graftversus-host disease (GvHD) prophylaxis consisted of cyclosporine. The patient developed fever in the first posttransplant days requiring broad-spectrum antibiotic therapy. Other complications developed, including respiratory insufficiency, treated with inotropic and diuretic drugs. On day 29 postinfusion, she received a prophylactic DLI of 2 Â 10 5 lymphocytes and developed grade II GvHD with skin and liver involvement treated with methylprednisolone. On day 55, positive antigenaemia for cytomegalovirus was detected and managed sequentially with foscarnet, ganciclovir and G-CSF. Capillary leak syndrome appeared as a complication of the G-CSF. After 3 months of in-patient treatment the patient recovered a normal complete blood count, the lymphadenopathy dissolved and she was discharged in good general condition.
After 4 weeks, she was readmitted to hospital with submandibular lymphadenopathy, blurred vision, sweats and pancytopenia. Complete blood count showed leukocytes 1.95 Â 10 9 /l, haemoglobin 80.5 g/l and platelets 11 Â 10 9 /l. The LDH was 18.7 mkat/l. Bone marrow smears revealed small CLL lymphocytes and 37% of large-cell lymphoid cells with immature nuclei, prominent nucleoli and deeply staining blue cytoplasm (Figure 2 ). Similar surface immunophenotypic expression was documented in both small and large lymphoid cells by flow cytometry because a homogeneous cell population was observed. B cells were CD5+, CD23+, FCM7À, and exhibited weak expression of surface immunoglobulins, CD22 and CD79b. Bone marrow biopsy was hypercellular with nodular and interstitial infiltration by small lymphocytes with condensed nuclei, which were mixed with numerous big pleomorphic cells with paraimmunoblastic transformation. EBV could not be identified, as the large cells were negative for LMP1. Donor chimerism studies were performed on peripheral blood and bone marrow blood samples and showed mixed chimerism with a drop in the percentage of donor hematopoiesis ( Figure 3) . A diagnosis of RS was made. Cyclosporin A was withdrawn and a single DLI of 1 Â 10 7 CD3/kg was given on day 131 post-transplant. She then developed grade II skin GvHD. Resolution of systemic symptoms and progressive reduction in lymphadenopathy occurred within 2 weeks. Slow recovery of a normal blood count was accompanied by restoration of full donor chimerism. The LDH returned to normal.
After 18 months of the therapeutic DLI, the patient continues in complete remission. There is no lymphadenopathy, cytopenia, no pathologic cells can be identified by flow cytometry and full donor chimerism persists in the peripheral blood as well as in the bone marrow ( Figure 3 ).
Discussion
High-dose chemotherapy with autologous or allogeneic SCT is effective at producing complete remissions in patients with CLL. 6 Allogeneic SCT is a treatment with considerable transplant-related toxicity, but it is able to induce long-lasting complete remissions 6, 7 with a negative minimal residual disease status 8 and low relapse rates. 9 In a recent study, the efficacy of allogeneic SCT was evaluated in eight patients who had CLL in Richter's transformation. Three of the eight patients (38%) attained durable remissions, and, remarkably, two of these three had received a nonmyeloablative regimen. 4 These responses are probably due to an allogeneic GVL effect.
In our patient, we observed a short complete remission after allogeneic SCT despite significant transplant-related toxicity. When the relapse was detected and high-grade lymphoma cells were identified coexisting with a population of remaining CLL, we attempted to enhance the GVL effect directed against both malignancies. Immunosuppression with cyclosporine A was withdrawn and therapeutic DLI (1 Â 10 7 CD3/kg) given. Although DLIs may cause significant toxicities inducing acute and chronic GvHD, 10 there is increasing evidence that immunosuppression withdrawal with or without DLIs is able to induce remission in patients with CLL, RS, low-and intermediate-grade lymphoma 11 as well as in relapsed NHL. 12 Rondon et al 13 reported a case of CLL with persistent lymphocytosis and lymphadenopathy after allogeneic SCT who achieved complete remission after receiving DLI on day 87. Similarly, our patient experienced a progressive reduction of submandibular lymphadenopathy, and bone marrow infiltration by malignant cells and recovered a normal blood count following the DLI. LDH level became normal and complete donor chimerism was instituted in the peripheral blood as well as in the bone marrow. We believe that the GVL effect was responsible for both the disappearance of the large B-lymphocytes, the small lymphocytes of CLL, and the maintenance of long-lasting remission.
The origin of the malignant cell population in high-grade lymphomas complicating low-grade lymphoproliferative disorders remains controversial. 1, [14] [15] [16] [17] Two hypotheses attempt to explain the origin of RS. The first one, which is supported by more authors, suggests a cellular transformation evolving from the original B-cell clone. 15, 16 On the other hand, some investigators believe in a biclonal origin of the high-and low-grade malignancies, with the new lymphoproliferative disorder arising in an immunosuppressed host. 15, 17 In both theories, the immunosuppressive and mutagenic role of chemotherapeutic drugs, in addition to immune system alteration due to B-CLL play a significant role. 1, 15 Chemotherapeutic agents and preparative regimens for allogeneic SCT with subsequent immunosuppressive therapy are deemed to be contributing factors. 15 The long-term immunodeficiency seen in CLL might be a potential etiological factor, with a causal relationship similar to that seen in NHL associated with HIV infection, congenital immunodeficiencies and immunosuppression after organ transplantation. 18 We believe that the presence of a similar immunoglobulin rearrangement pattern in both small and large lymphoid cells, and the quick disappearance of both populations, suggest a unique clonal origin of CLL and RS in this patient. However, molecular studies are needed to confirm clonality.
RS was managed with immunosuppressive drug withdrawal and a single DLI. This case provides further evidence for the allogeneic GvL activity directed against CLL and high-grade NHL originating from CLL and illustrates for the first time, to our knowledge how DLIs may provide effective and prolonged response in RS after allogeneic SCT. 
